Our Research Methodology
We are advancing the next generation of therapeutics that restore the effectiveness of antibiotics compromised by bacterial resistance. Our platform combines AI-driven discovery with real-world laboratory validation and clinical preparation to combat infectious diseases.
In Silico Evaluation
Our process begins with powerful computational analysis. We sift through vast datasets to identify promising candidates with high potential for therapeutic efficacy.
Live Bacteria Evaluation
Selected candidates undergo rigorous in-vitro testing against both gram-positive and gram-negative bacterial pathogens. By themselves, these compounds show no antibacterial activity, reducing the risk of resistance development. We have confirmed the safety of our agents via human tissue culture and animal studies.
Compound Optimization & Combination Discovery
Promising compounds are refined and tested in combination with existing antibiotics to restore their activity. Additional combinations are under development and will be covered in future patent filings.
Research
We have further confirmed the safety of our agents via human tissue culture studies. Phase I trials on healthy volunteers will establish safety and dosage, followed by trials on infected individuals to test efficacy in real-world conditions.
Financial & Clinical
AlBioDiscovery is targeting a $20M seed round to fund synthesis and testing of additional compounds, in-vitro validation, and Phase I & II clinical trials in the US and abroad.
Experimental Validation & Results
Anti bacterial activity of compound AB-4 on Acinetobacter baumannii
Docking an Fmoc-Peptide to E.coli TEM-1 beta-Lactamase
Protecting Our Innovation
We have filed patents covering our compounds and agent-antibiotic combinations.